OmniScience combines deep clinical data science expertise with frontier AI engineering to give clinical development teams the operating layer their trials deserve.
Clinical trials are one of humanity's most important scientific endeavors. They are also one of its most complex operational challenges. OmniScience was founded on the belief that the intelligence tools available to clinical development teams were not keeping pace with the complexity of modern trials — and that closing that gap could meaningfully accelerate the delivery of life-changing medicines to patients who need them.
Vivo is that operating layer. Built for the teams closest to trial execution — and designed to scale from one study to an entire portfolio.
Behind every clinical trial is a patient waiting for an answer. An Alzheimer's family waiting for a treatment. A child waiting for a rare disease therapy. An oncology patient waiting for a next option. Clinical trial delays are not abstract operational failures — they are measured in time that patients and families do not have.
OmniScience exists because the operating tools available to clinical development teams were leaving time on the table. We believe the intelligence gap between data and action can be closed — and we are building the platform to close it.
The founding team builds deep expertise in clinical data science, AI engineering for regulated industries, and life sciences domain problems across complex multi-source clinical programs.
Mercury Data Science grows as a clinical data science practice, working across early- and late-stage trials, global programs, and complex multi-system data environments — building the domain expertise that Vivo is now built on.
Mercury Data Science becomes OmniScience, reflecting the company's evolution from services to a product-led platform strategy. Vivo launches as the flagship product: a governed AI control tower for clinical development.
Vivo integrates with Veeva and LabConnect. OmniScience joins NVIDIA Inception, Google for AI Startups, and J&J JLABS. Named in IDC MarketScape. DCRI Program Finalist. Customer base expands across oncology, CNS, rare disease, and immunology programs.
Vivo scales across clinical functions, portfolio programs, and large pharma enterprise AI ecosystems. OmniScience expands headless and API-first deployment patterns. Agentic monitoring and portfolio intelligence reach general availability.
Every delay in clinical development is measured in time patients do not have. This grounds every product decision and every partnership we take on.
We build what clinical development teams actually need — not what is easy or already familiar. The best product is the one that solves the real problem.
We build with our customers, not for them. The best feedback is a clinical team using Vivo in an active trial and telling us what is not working.
The best solutions come from understanding the problem deeply. We ask why. We investigate. We stay close to the science and the operational reality of clinical trials.
The work we do is hard and the domain is demanding. We take care of each other, stay direct, and build an environment where great people can do the best work of their careers.
We are not a generic AI company that moved into clinical trials. We are a clinical development company that builds AI. That distinction shapes everything we build.
OmniScience is headquartered in the Texas Medical Center — the world's largest medical center and a hub for life sciences innovation, clinical research, and health technology development.
Join the Team
We are building the intelligence layer for modern clinical trials. If you are passionate about clinical data, AI engineering, or life sciences product development — we would love to talk.
See Open Roles →